

WELLINGTON

Level 6, 44 The Terrace PO Box 2351, Wellington 6140 New Zealand Tel: +64 4 924 3600

AUCKLAND

Level 13, 55 Shortland Street PO Box 105-222, Auckland 1143 New Zealand Tel: +64 4 924 3600

www.comcom.govt.nz

15 August 2017

Glaxosmithkline Consumer Health Care New Zealand Limited C/o Bird & Bird Lawyers Level 11 68 Pitt Street Sydney NSW 2000 Australia

By Email: lynne.lewis@twobirds.com

Dear Directors

Glaxosmithkline Consumer Health Care New Zealand Limited - Fair Trading Act 1986: Warning – twin products

- 1. The Commerce Commission (the **Commission**) has been investigating the distribution and marketing of certain Voltaren and Panadol branded products in New Zealand by Glaxosmithkline Consumer Health Care New Zealand Limited (**GSK NZ**) under the Fair Trading Act 1986 (the **Act**).
- 2. Specifically, we have investigated the Voltaren and Panadol products pairs below (together called **the products**) each of which contain the same ingredients:
 - 2.1 Voltaren Emulgel / Voltaren Osteo Gel;
 - 2.2 Panadol Osteo Caplets / Panadol Back & Neck Long Lasting;
 - 2.3 Panadol Rapid / Panadol Back & Neck Pain Relief; and
 - 2.4 Panadol Cold & Flu Max + Decongestant / Panadol Sinus Pain & Congestion Relief.
- We have now completed our investigation and are writing to warn you that the packaging and marketing for the products were likely to have breached sections 10 and/or 13(e) of the Act.
- 4. Section 10 of the Act prohibits traders from engaging in conduct that is liable to mislead the public as to the nature or characteristics of goods or their suitability for a purpose.

- 5. Section 13(e) of the Act prohibits traders from making false or misleading representations that goods have performance characteristics, uses or benefits.
- 6. GSK NZ does not consider it has breached the Act but has advised that since the investigation began, it has discontinued three of the products (Panadol Back & Neck Long Lasting, Panadol Back & Neck Relief and Panadol Sinus & Congestion Relief) and that the packaging for Voltaren Osteo Gel and parts of the Voltaren website that relate to Osteo Gel have been amended to include the statement "Same effective formula as Emulgel".

The investigation

- 7. GSK NZ cooperated fully with the Commission and supplied information and product packaging in relation to the distribution and sales in New Zealand of the products and originating products including documents in relation to the history of relevant Medsafe approvals.
- 8. The investigation showed that each of the products has the same active ingredients but have been marketed for different therapeutic purposes.
- 9. We have investigated whether specific representations made by GSK NZ, on packaging and in advertising (including website advertising) for the products created the overall impression that the specific product:
 - 9.1 had been specially formulated for the purpose stated on the product packaging; and/or
 - 9.2 was more effective for treating the named purpose of the product than the originating product; and/ or
 - 9.3 was solely effective in treating the pain state named on packaging for the product.
- 10. Copies of the packaging with representations for the products and originating products investigated are at **Attachment A.**

Voltaren Emulgel / Osteo Gel

- 11. Emulgel and Osteo Gel are sold as two separate topical gel products but have identical ingredients.
- 12. Emulgel is marketed for general inflammation of the muscles, joints, tendons and ligaments due to injury, as well as back, neck and shoulder pain. Osteo Gel is marketed specifically for occasional pain and inflammation in mild forms of osteoarthritis of the knees and fingers.
- 13. Our investigation confirmed that Osteo Gel is identical to Emulgel.

Packaging

- 14. We identified aspects of the Osteo Gel packaging which in our view was likely to create the impression that Osteo Gel had been specifically formulated to treat mild forms of osteoarthritis of the knees and fingers, and was more effective or solely effective in treating mild forms of osteoarthritis of the knees and fingers than other products including Emulgel. This impression was likely to be created by:
 - The reference to "Osteo" in the name of the product.
 - Statements on the front and back of the product that it is "for the temporary relief of local pain and inflammation associated with mild forms of osteoarthritis of the knees and fingers".
 - The stylised picture of a knee joint on the packaging.
 - The sale of Osteo Gel in different pack sizes with different price points to Emulgel. This may have added to the impression that Osteo Gel is a different and more specialised product than Emulgel.
- 15. The potentially misleading impression given by the original packaging was compounded when Osteo Gel was contrasted with the packaging for Emulgel which did not refer to osteoarthritis as a specific indication on its packaging and only referred to "soft tissue rheumatism" on the back of the product in small print. There was no reference to osteoarthritis on the Emulgel packaging leaflet insert.
- 16. If consumers purchased both products or read the information for each they were likely to form the view that the products were different and that they treated different ailments.

Website

- 17. The content of the Voltaren website at www.voltaren.co.nz was also likely to give the impression that Osteo Gel is a specialised product. Copies of the relevant website pages are at Attachment B. The website stated in respect of Osteo Gel that:
 - It provided "targeted relief for mild forms of osteoarthritis".
 - That "the patented technology in Voltaren Osteo Gel helps the gel to penetrate deeply into the skin to enhance delivery of diclofenac to the site of pain".
- 18. The website also provided different information about Emulgel that reinforced the impression that both Emugel and Osteo Gel were targeted products with special indications. For example it stated:
 - "Voltaren Emulgel Targeted relief for muscle strains and sprains".

- "Targeted relief right where you need it".
- Emulgel "is used to treat inflammation of muscles, joints, tendons and ligaments, due to trauma (e.g. sports injuries, sprains and strains), soft tissue rheumatism and localised rheumatic conditions (e.g. bursitis, aches and pains)."
- "the Emulgel technology helps the gel to penetrate deeply into the skin to enhance delivery of diclofenac to the site of pain".
- 19. During the period of the Commission's investigation, GSK NZ amended the Osteo Gel product page of the Voltaren website to include the statement "same effective formula as Emulgel" and removed the reference to "targeted relief for mild forms of osteoarthritis". GSK NZ amended the product comparison page to remove any reference to Osteo Gel, and to only refer to the new Osteo Gel 12 Hourly, which is double the strength of Emulgel/ Osteo Gel.

Advertising

- 20. Advertising for Osteo Gel may have also created a misleading impression:
 - 20.1 The original television commercial aired in 2011, as part of the Family Health Diary advertorial, described Osteo Gel as a 'new' product. Only the packaging of the product was new at the time, as Emulgel had been on the market since 1991 as a prescription only medicine, and from 2006 as a general medicine.
 - 20.2 In a launch advertorial in the print edition of the Family Health Diary from November to December 2011, Osteo Gel was also described as a "new treatment". This advertisement also made the statement that "Voltaren Osteo Gel's targeted action has been shown to reach therapeutic levels at the site of pain, providing clinically significant improvement in pain after one week".
 - 20.3 Osteo Gel was widely promoted between 2011 and 2015 including television advertisements referring to it exclusively as a treatment for osteoarthritis.
- 21. The representation in 2011 that Osteo Gel was a 'new product' is particularly concerning. The product was new if 'product' means packaging and 'get up'. But the formulation was the same as Emulgel which had been on the market since 2006 for general sale. In our view consumers were likely to have inferred from the 'new product' and 'new treatment' representations that Osteo Gel was a new and different means of treating osteoarthritis, when it was neither.
- 22. While Osteo Gel advertising is historical (and not continuing), we consider that the representations outlined above would likely amount to a breach of the Act.

GSK NZ position

- Osteo Gel product is in fact a different product to Emulgel although it has the same active and inactive ingredients. It pointed to the difference in recommended usage periods between the two, with three weeks being medically indicated for Osteo Gel, and a maximum of two weeks for Emulgel. These usage periods were approved by Medsafe on the basis of medical trials. GSK NZ also claimed that the product size and the specially designed 'easy open' triangular cap was an important feature that distinguished it from Emulgel.
- 24. GSK NZ also emphasised that the customers purchasing Osteo Gel with osteoarthritis were unlikely to be the same demographic as customers using Emulgel as osteoarthritis suffers tend to be older and under the care of a physician unlike consumers suffering from sprain and strains and other soft tissue injuries.
- 25. GSK NZ has, however, taken steps to address the Commission's concerns with the introduction of new product labelling for Osteo Gel that includes a statement on the front of packaging for Osteo Gel "same effective formula as Emulgel". This statement has also been added to the Osteo Gel product page on the Voltaren website.

Panadol Osteo Caplets / Panadol Back & Neck Long Lasting

- 26. GSK NZ has also marketed the Panadol Osteo Caplets and Panadol Back & Neck Long Lasting Caplets products for different purposes even though they have identical active ingredients. A copy of the packaging is at Attachment A.
- 27. We were concerned that the packaging and marketing for the products created the impression that:
 - 27.1 each product was specifically formulated or designed for the purpose of treating mild forms of osteoarthritis or back and neck pain respectively;
 - each product was solely effective in providing relief of persistent pain associated with osteoarthritis or back and neck pain respectively;
 - 27.3 each product was more effective for treating osteoarthritis or back and neck pain than the other product.
- 28. The Osteo Caplets packaging stated that the product was for "Relief of persistent pain associated with Osteoarthritis. Up to 8 hours relief 96 Bi-layer caplets". The back stated "Use Panadol Osteo for Panadol Osteo is effective for the relief of persistent pain associated with Osteoarthritis".
- 29. The Panadol Back & Neck Long Lasting packaging stated that it was for "Relief of back, neck & shoulder pain" and it provided "Up to 8 Hours relief". The back confirmed that the product "provides effective relief of persistent back, neck &

shoulder pain for up to 8 hours" and that it should be used for "Back Pain, Neck Pain, Shoulder Pain".

Packaging

- 30. In our view, the following aspects of the packaging for the Panadol Osteo product were likely to create the impression that it was specifically formulated, designed, effective and / or solely effective in treating osteoarthritis:
 - the reference to 'Osteo' in the product name;
 - visual representations of the bones in the knee joint with 'cooling' blue colour;
 - the statement "Relief from persistent pain associated with mild forms of osteoarthritis"; and
 - the statement "Panadol Osteo is effective for the relief of persistent pain associated with Osteoarthritis".
- 31. The aspects of the packaging for the Panadol Back & Neck Long Lasting were also likely to have created the impression that it was specifically formulated, designed and / or solely effective in treating back and neck pain:
 - The reference to the Back and Neck in the product name;
 - Visual representations showing red/orange circles depicting pain areas given relief by the product together with the statements:
 - "relief of back, neck and shoulder pain";
 - "Panadol Back & Neck Long Lasting is a sustained release formulation that provides effective temporary relief of persistent back, neck & shoulder pain for up to 8 hours";
 - "Use Panadol Back & Neck Long Lasting for Back Pain, Neck Pain, Shoulder Pain".

Advertising

- 32. There was a range of advertising in customer newsletters and other print advertisements between 2010 and 2015 for Panadol Osteo Caplets which made various statements such as:
 - "As the name Panadol Osteo suggests, it has been specifically formulated to combat the pain associated with osteoarthritis." (2010);
 - "Panadol Osteo has been specifically designed for people with osteoarthritis, offering sustained pain relief for up to eight hours" (2012);

- "Unique Bi-Layer Technology" (2013);
- "Panadol Osteo has been specifically designed for people with Osteoarthritis ..." (2013);
- "Only Panadol Osteo has unique paracetamol bi-layer technology" (2014);
- "Panadol Osteo brings you a unique bi-layer tablet that is gentle on the stomach...unique bi-layer technology to fight osteoarthritis pain" (2014).
- 33. The limited advertising for the Back & Neck Long Lasting Caplets during this period also highlighted the "unique bi-layer formulation" of the product.

Website representations

- 34. Osteo Caplets and Back & Neck Long Lasting Caplets had product pages on the Panadol Website. Representations on the page relating to Back & Neck Long Lasting Caplets on 24 December 2015, referred to fact that:
 - the unique bi-layer paracetamol formulation releases one layer quickly for rapid onset action, while the second layer is released slowly over the day or night to provide prolonged pain relief...
- 35. We were concerned that the product labelling and advertising for the Panadol Osteo and Back & Neck Long Lasting product may have also been misleading because although they have a "bi-layer" formulation that provides slow release of paracetamol and they have a slightly higher dose of paracetamol than standard tablets it was not specifically formulated for osteoarthritis or neck and back pain. We do not understand that Panadol Osteo or Panadol Back & Neck Long Lasting to have special efficacy for osteoarthritis or back and neck pain apart from this slow release effect.
- 36. Panadol Osteo or Panadol Back & Neck Long Lasting was not solely effective for providing persistent pain associated with osteoarthritis or back and neck pain. The products were equally indicated by Medsafe for muscle aches and pains and for the temporary relief of pain and discomfort associated with headache, tension headache, period pain, toothache and pain after dental procedures, cold and flu and fever.
- 37. The Panadol Back & Neck Long Lasting product has been discontinued since January 2016.

Panadol Rapid / Panadol Back & Neck Relief

38. Similar issues arise with the product packaging and marketing of Panadol Back & Neck Pain Relief which had the same ingredients as the general fast acting pain relief product Panadol Rapid. A copy of the packaging is at Attachment A.

- 39. Panadol Rapid was indicated for general pain relief which was specified on the back of the packaging to include "Headache/ Tension Headache; Migraine Headache; Cold & Flu Symptoms; Muscular Aches; Toothache; Period Pain; Helps reduce Fever".
- 40. By contrast the Panadol Back & Neck Pain Relief product stated that it was for "fast effective temporary relief of Backache, Neck ache, Shoulder Pain."
- 41. GSK NZ advised during the course of the Commission's investigation that it had discontinued the Panadol Back & Neck Relief product from March 2016.

Panadol Cold & Flu Max + Decongestant / Panadol Sinus Pain & Congestion Relief

- 42. These products were also made from the same active ingredients. The labelling raised similar concerns for the Commission as identified with the other Panadol products.
- 43. We were concerned with that the labelling gave the overall impression the Panadol Sinus Pain & Congestion Relief product was a specially formulated product, was more effective and solely effective in treating sinus pain and congestion, even though the Panadol Cold & Flu Max + Decongestant product was made from exactly the same ingredients.
- 44. There does not appear to have been much advertising for the Sinus Pain Relief & Congestion product except on the website. We do not have concerns with the product advertising for either the Sinus Pain Relief or the Cold & Flu products.
- 45. When the issues discussed above were raised with GSK NZ, it responded by confirming that the Sinus Pain & Congestion Relief product was being discontinued from July 2016.

The Commission's view

- 46. In the product cases identified, the Commission's view is that GSK NZ's conduct is likely to have breached sections 10 and/or 13(e) of the Act.
- 47. In our view the packaging and some marketing for the products in each case misrepresented the characteristics and / or suitability of the products. The packaging and marketing created the overall impression that the product had been specifically formulated, was more effective and / or solely effective in treating the stated indications for that product when that was not the case. In fact, the product had the same efficacy for treating either the same or broader pain indications or symptoms as represented on the originating product packaging.
- 48. The removal of the products Panadol Back & Neck Long Lasting, Panadol Back & Neck Relief and Panadol Sinus Pain & Congestion Relief from the market and the amendment to the Voltaren Osteo Gel packaging and website, addressed the Commission's concerns. We have also taken into account the fact that GSK NZ sold

- the products at the same price, except that Osteo Gel products were sold in larger pack sizes.
- 49. We recommend that you seek legal advice and encourage you to regularly review your compliance procedures and policies.
- 50. While we will not be taking any further action against GSK NZ at this time, we will take this warning into account if this conduct continues or if you engage in similar conduct in the future.
- 51. We may also draw this warning to the attention of a court in any subsequent proceedings brought by the Commission against GSK NZ.
- 52. This warning letter is public information. We may make public comment about our investigations and conclusions, including issuing a media release or making comment to media.

The Commission's role

53. The Commission is responsible for enforcing and promoting compliance with a number of laws that promote competition in New Zealand, including the Act. The Act prohibits false and misleading behaviour by businesses in the promotion and sale of goods and services.

Penalties for breaching the Fair Trading Act

- Only the courts can decide if there has actually been a breach of the Act. The court can impose penalties where it finds the law has been broken. A company that breaches the Act can be fined up to \$600,000 and an individual up to \$200,000 per offence.
- 55. You should be aware that our decision to issue this warning letter does not prevent any other person or entity from taking private action through the courts.

Further information

- 56. We have published a series of fact sheets and other resources to help businesses comply with the Act and the other legislation we enforce. These are available on our website at www.comcom.govt.nz. We encourage you to visit our website to better understand your obligations and the Commission's role in enforcing the Act.
- 57. You can also view the Act and other legislation at www.legislation.co.nz.

58. Thank you for your assistance with this investigation. Please contact Catherine Butterworth, Chief Adviser on 09 920 3485 or by email at catherine.butterworth@comcom.govt.nz if you have any questions about this letter.

Yours sincerely

Stuart Wallace

Consumer Manager

Competition

ATTACHMENT A

Voltaren Emulgel



For temporary relief of local pain and inflammation in acute soft tissue injuries and localised soft tissue rheumatism including sprains, tendinitis, bursitis and sports injury.

DOSAGE:

Rub gently into the affected area 3 or 4 times daily. Do not use for more than 2 weeks except on medical advice. See pack leaflet for full information and warnings.

DO NOT USE IF TUBE SEAL IS BROKEN

Store below 30 °C.

Avoid contact with eyes. For external use only.


Contains isopropyl alcohol as a preservative.

Sponsors of:



Voltaren Osteo Gel





Panadol Osteo Caplets



E84222

PANADOL OSTEO is a bi-layer formulation that has an immediate and a susteined tree has a face of paracetamol, providing long-lasting pain relief for up to 8 hours.

USE PANADOL OSTEO FOR

Panadol Osteo is effective for the relief of persistent pain-associated with Osteoarthritis. Suitable for: • People with stomach ulcers • Breastfeeding mothers

DO NOT USE PANADOL OSTEO

- If you are allergic to paracetarnol

 If you are allergic to paracetarnol

 More frequently than every 6 hours

 If using any other medicines containing paracetamol
 For children below age 12
 For more than 48 hours for children aged 12-17 except
 on medical advice

 For more than a few days at a time in adults except
 on medical advice

 If any of the seels on this packaging are broken
 If the packaging use-by date has expired

CHECK WITH YOUR DOCTOR BEFORE USING IF YOU

- Have liver or kidney problems
 Are taking warfarin (a medicine used to thin the blood)

- Doses should be equally spaced throughout the day
 Can be taken with or without food
 The captes must not be crushed
 Store below 30°C.

(B)135518 EXP JAN 19

STOP USE AND TELL YOUR DOCTOR IF YOU

Have an allergic reaction, shortness of breath or wheezing after taking Panadol.

EACH CAPLET CONTAINS

665mg Paracetamol • No gluten, lactose or sugar

KEEP TO THE RECOMMENDED DOSAGE

If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 131 126: NZ 0800 764 766) or go to the hospital immediately even if you feel well because of the risk of delayed, serious liver damage if left untreated.

Panadol Back & Neck Long Lasting





Panadol Rapid





Panadol Back & Neck






Panadol Cold & Flu Max + Decongestant





Panadol Sinus Pain & Congestion Relief





Attachment B

Website pages



Voltaren Osteo Gel

FAST ACTING

Voltaren® Rapid 12.5 liquid capsules (/brands/fastacting/voltaren-rapid-125liquid-capsules)

Voltaren® Rapid 25 tablets (/brands/fastacting/voltaren-rapid-25tablets)

LONG-LASTING FOR STRONGER PAIN

Voltaren® Rapid 25 tablets (/brands/long-lasting-forstronger-pain/voltarenrapid-25-tablets)

OSTEOARTHRITIS PAIN RELIEF

Voltaren® Osteo Gel (/brands/osteoarthritispain-relief/voltarenosteo-gel)

TREAT THE SOURCE

Voltaren® Emulgel® (/brands/treat-thesource/voltaren-emulgel)

Voltaren® Rapid 12.5 tablets (/brands/treat-thesource/voltaren-rapid-125tablets)

Voltaren® Rapid 25 tablets (/brands/treat-thesource/voltaren-rapid-25tablets)

PRODUCT COMPARISION (/BRANDS/PRODUCT-COMPARISON)

Voltaren® Osteo Gel

Targeted relief for mild forms of osteoarthritis

Usage

Voltaren Osteo Gel is clinically proven for temporary relief of local pain and inflammation in mild forms of osteoarthritis of the knees and fingers.

Effect

Voltaren Osteo Gel contains the non-steroidal anti-inflammatory drug (NSAID), diclofenac. Diclofenac works to relieve pain and reduce inflammation (swelling). The patented technology in Voltaren Osteo Gel helps the gel to penetrate deeply into the skin to enhance delivery of diclofenac to the site of pain. Voltaren Osteo Gel has a cooling, moisturising effect with no strong odours.

Application:

Aduits and children over 12 years: rub the gel gently into the affected area. Apply three or four times each day. The amount you will need will depend on the size of the affected area. Usually an amount ranging in size from a cherry to a walnut will be enough. Use for up to three weeks, if needed.

Pack size:

Voltaren Osteo Gel is available in 75 g and 150 g tubes.

You may also be interested in:

Joint pain/osteoarthritis (/pain/joint-pain)

PRODUCTS (/PRODUCTS)

FAST ACTING (PRODUCTS/FAST-ACTING)
LONG LASTING FOR STRONGER PAIN (PRODUCTS/LONG-LASTING-FOR-STRONGER.PAIN)
OSTEOARTHRITIS PAIN RELIEF (PRODUCTS/OSTEOARTHRITIS-PAIN-RELIEF)
TREAT THE SOURCE (PRODUCT COMPARISON (PRODUCT COMPARISON)

PAIN (/PAIN)

WHAT IS PAIN? (PAINWHAT-IS PAIN)
WHAT CAUSES PAIN (PAINWHATCAUSES PAIN)
IDENTIFY YOUR PAIN (PAIN/IDENTIFYYOUR PAIN)
ABOUT VOLTAREN» (PAIN/ABOUTVOLTAREN)

KEEP MOVING (/KEEP-MOVING)

EXERCISE PROGRAMS (KEEP-MOVING/EXERCISE-PROGRAMS) EVERYDAY HEALTHY MOVEMENTS (KEEP-MOVING/HEALTHY-EVERYDAY-MOVEMENTS) NEWS & UPDATES (/NEWS-AND-ARCHIVES) FAQS (/PAGES/FAQ) CONTACT (/PAGES/CONTACT-US) SITE MAP (/SITEMAP)

https://www.voltaren.co.nz/brands/osteoarthritis-pain-relief/voltaren-osteo-gel

24/12/2015

Product Comparison

	Your situation	Use for	Format	Benefits	Dosage	Duration of use	Package stre	
Voltaren [®] Emulgel [®] (productureat-the- source/voltaren-emulgel)	You want targeted relief right where you need it	Inflammation of musdes, joints, tendons and ligaments due to injury, as well as back, neck and shoulder pain	Gel	Saathing, cooling, law odaur	Adults and children over 12 years: apply 3-4 times a day, Follow full directions in pack leaflet,	2 weeks, if needed	20 g. 50 g. 100 g. 120 g tube	
Voltaren® Osteo Gel Uproductulosteoarthritis-pain- rell'et/voltaren-osteo-gel)	You want targeted relief for mild forms of osteoarthritis	Occasional pain and inflammation in mild forms of osteoarthritis of the knees and fingers	Gel	Southing, cooling, law odour	Adults and children over 12 years: apply 3-4 times a day. Follow full directions in pack leaflet.	3 weeks, if needed	75 g. 150 g tube	
Voltaren [®] Rapid 12.5 tablets Uproductutureat-the- source/voltaren-rapid-125-tablets)	You want a treatment dinkelly proven to restore your movement sooner	Mild to moderate musde, back, and rheumatic pain	Tablets	Small and easy to swellow	Adults and children over 14 years: 1 or 2 tablets every 4-6 hours as required, Follow full directions in pack leaflet.	A few days, if needed	10, 20 or 30 tablet pack	
Voltarene Rapid 12.5 Equid capsules (Uproductufast-acting/soltaren-rapid-125-Equid-capsules)	You want fast- absorbing Equid capsules	Mild to moderate musde, back, and rheumatic pain	Liquid Capsules	Small, easy to snallow, with Equid capsule technology for fast absorption	Adults and children over 14 years: 1 or 2 capsules every 4-6 hours as required. Follow full directions in pack leaflet.	A few days, if needed	20 liquid capsule pack	
Voltaren Rapid 25 tablets (productalong dating-for- stronger-pain/voltaren-rapid-25- tablets)	You want long- lasting relief for tough pain	Painful conditions where swelling is a problem, such as back or joint pain, musde strains, sprains or tendinitis	Tablets	Fast-acting and long- lasting for tough pain	Adults and children over 14 years: 1 or 2 tablets every 8 hours as required. Follow full directions in pack leaflet.	A few days, if needed	20 or 30 tablet pack	
PRODUCTS (PRODUCTS)	PAIN (PAIN)		KEEP MC	KEEP MOVING (KEEP-MOVING)				
FAST ACTING (PRODUCTSFAST- ACTING) LONG LASTING FOR STRONGER PAIN (PRODUCTSLONGLASTING-FOR- STRONGER-PAID) OSTIOANEDITE PAIR PLUSE (PRODUCTSOSSIOANEDITE-PAIR- RUSE) THAT THE SOURCE (PRODUCTSTEAST-INE-SOURCE) RODUCT CONSTRUCTS	WHAT IS PART (PARWHAT-G-PART) WHAT CAUSE PART (PARWHAT- CAUSEPAR) IOCHTEY YOUR PART (PARWENTEY- YOUR PART) ABOUT VOITABLES (PARWENOUT- VOITABLES)		THREST MOSTAUS (MEET MOSTAUSTE CREATER CONTROL OF SPORTAL THREST MOSTAUSTS (MEET MOSTAUSTS) (MEET MOSTAUGHEL THREST MOSTAUSTS) MOSTAUNTS)		ARCHR. FAQS (I	nida Sundatis (rinas-aro- Moratis Aadi (fracesfa) Contact (rrecipatis Contact-us) Itt map (sittima)		
(FRODUCTS/TREAT-THE-SOURCE) FRODUCT COMPARISON								